# EDGAR Filing Document

**Accession Number:** 0000012239
**File Stem:** 0001213900-26-061564
**Filing Date:** 2026-5
**Character Count:** 10673
**Document Hash:** 0bb5e4f215134243a1c8d3c0e94dc29c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-061564.hdr.sgml**: 20260527

**ACCESSION NUMBER**: 0001213900-26-061564

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20260522

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260527

**DATE AS OF CHANGE**: 20260527

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Dominari Holdings Inc.
- **CENTRAL INDEX KEY:** 0000012239
- **STANDARD INDUSTRIAL CLASSIFICATION:** SECURITY BROKERS, DEALERS & FLOTATION COMPANIES [6211]
- **ORGANIZATION NAME:** 07 Trade & Services
- **EIN:** 520849320
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41845
- **FILM NUMBER:** 261027304

**BUSINESS ADDRESS:**
- **STREET 1:** 725 FIFTH AVENUE
- **STREET 2:** 22ND FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022
- **BUSINESS PHONE:** (212) 393-4540

**MAIL ADDRESS:**
- **STREET 1:** 725 FIFTH AVENUE
- **STREET 2:** 22ND FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AIkido Pharma Inc.
- **DATE OF NAME CHANGE:** 20210111

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Aikido Pharma Inc.
- **DATE OF NAME CHANGE:** 20200317

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SPHERIX INC
- **DATE OF NAME CHANGE:** 20010815

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or Section 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): May 22, 2026**

**Dominari Holdings Inc.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-41845** | **52-0849320** |
| (State or other jurisdiction<br> of incorporation) | (Commission File Number) | (IRS Employer<br> Identification No.) |

---

**725 5th Avenue, 22nd Floor**

**New York, NY 10022**

**(212) 393-4540**

**(**Address, including Zip Code and Telephone Number, including

Area Code, of Principal Executive Offices)

**Not Applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, $0.0001 par value | DOMH | The Nasdaq Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 1.01. Entry into a Material Definitive Agreement.**

On May 22, 2026, Dominari Holdings Inc. (the "**Company**"), a Delaware corporation, in a successful effort to reduce market overhang from outstanding warrants, entered into inducement agreements (the "Inducement Agreements") with certain holders (the "**Holders**") of Series B warrants (the "**Series B Warrants**") of the Company to purchase up to an aggregate of 3,133,880 shares of the Company's Common Stock, par value $0.0001 per share ("**Common Stock**"), originally issued to the Holders in connection with the Company's previous originally issued to the Holders on February 14, 2025, having an original exercise price of $4.22 per share (the "**Existing Warrants**"). The shares of Common Stock issuable upon exercise of the Existing Warrants are registered for resale pursuant to an effective registration statement on Form S-3 (No. 333-286648) previously filed with the U.S. Securities and Exchange Commission ("**SEC**") on April 21, 2025, and declared effective by the SEC on April 25, 2025.

Pursuant to the Inducement Agreements, the Holders were offered options to either (A) exercise for cash their Existing Warrants at a reduced exercise price of $2.50 per share ("**Option A**") or (B) exchange all, but not less than all, of such Holder's unexercised Existing Warrants for shares of Common Stock at an exchange ratio of 10:3, such that for every ten shares of Common Stock underlying the exchanged Series B Warrants, the Company would issue three shares of Common Stock (the "**Exchange Shares**") for no additional consideration ("**Option B**"). The Exchange Shares were issued in reliance upon the exemption from registration provided by Section 3(a)(9) of the Securities Act of 1933, as amended.

The Company expects to receive gross proceeds of approximately $3.67 million pursuant to Option A elections by Holders and expects to issue approximately 150,000 shares of Common Stock pursuant to Option B elections by Holders. Following entry into the Inducement Agreements and consummation of the related issuances and payments, the Company expects there to be approximately 1.2 million unexercised Series B Warrants outstanding.

The foregoing summaries of the Inducement Agreements do not purport to be complete and are subject to, and qualified in their entirety by, the form of such document attached as Exhibits 10.1 to this Current Report on Form 8-K, which are incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit** | **Description** |
| 10.1 | [Form of Inducement Agreement.](ea029220701ex10-1.htm) |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Dated: May 27, 2026 | **DOMINARI HOLDINGS INC.** | **DOMINARI HOLDINGS INC.** |
|  | By: | /s/ Anthony Hayes |
|  | Name: | Anthony Hayes |
|  | Title: | Chief Executive Officer |

---

## Exhibit 10.1

**Exhibit 10.1**

**DOMINARI HOLDINGS INC.**

May 18, 2026

Holder of Common Stock Purchase Warrants

Re: <u>Inducement Offer to Exercise and/or Exchange Common Stock Purchase Warrants</u>

Dear Holder:

Dominari Holdings Inc. (the "<u>Company</u>") is pleased to offer to you ("<u>Holder</u>", "<u>you</u>" or similar terminology) the opportunities set forth below with respect to outstanding Series B Common Stock Purchase Warrants issued to the Holder by the Company on February 14, 2025 (the "<u>Series B Warrants</u>" or the "<u>Warrants</u>" and the shares underlying the Series B Warrants, the "<u>Series B Warrant Shares</u>" or the "<u>Warrant Shares</u>"). **Capitalized terms used and not otherwise defined herein that are defined in the Warrants.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A) In consideration for the cash exercise of any Series B Warrants on or before 4 p.m. ET on May 22, 2026
(any such Warrants exercised prior to such time, the " <u>Exercised Warrants</u> "), the Exercise Price of such Exercised Warrants
shall be reduced to $2.50. The adjustment to the Exercise Price under this clause (A) shall only apply to Exercised Warrants and no other
Warrants. Your election to exercise the rights under this Clause A may be facilitated by the execution of this Agreement prior to such
date or the delivery of a duly executed Notice of Exercise prior to such date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B) With respect to the Series B Warrants that are not Exercised Warrants, the Holder shall have the right
to exchange all (but not less than all) of such unexercised Series B Warrants for shares of Common Stock for no additional consideration.
The exchange ratio shall be 10:3 such that for each ten (10) Warrant Shares being exchanged, the Company shall issue three (3) shares
of Common Stock (" <u>Exchange Shares</u> "). The Exchange Shares shall be issued hereunder in accordance with Section 3(a)(9)
of the Securities Act and as such the holding period of the Exchange Shares may be tacked on to the holding period of the Series B Warrants
and be freely tradeable pursuant to Rule 144.

The Holder may accept this offer by signing this letter agreement below, with such acceptance constituting Holder's irrevocable election on or before 4:00 p.m., Eastern Time, on May 22, 2026 (the "<u>Execution Time</u>").

Following the Execution Date the Company shall issue a press release disclosing the material terms of the transactions contemplated hereby and/or shall file a Current Report on Form 8-K with the Commission disclosing all material terms of the transactions contemplated hereunder.

This letter agreement shall be construed and enforced in accordance with the laws of the State of New York, without regards to conflicts of laws principles. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York,

Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby.

---

| |
|:---|
| Sincerely yours, |
| **DOMINARI HOLDING INC.** |
| By: |
| Name: |
| Title: |

---

Accepted and Agreed to:

Name of Holder: _________________________________________________

*Signature of Authorized Signatory of Holder:* __________________________

Name of Authorized Signatory: _____________________________________

Title of Authorized Signatory: ______________________________________

Number of Series B Warrants: ______________

Option A Elected: ________________

Option B Elected: ________________

DTC Instructions:

[Holder signature page to DOMH Inducement Offer]